Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents

British Journal of Dermatology

Volumn 147, Issue 6, 2002, Pages 1241-1243

  Sigurgeirsson, Bárour ^a,b   Paul, C ^b   Curran, D ^c   Evans, E G V ^d  

^a UNIVERSITY OF ICELAND   (Iceland)

^b France and Clinical Research ^*  (Iceland)

^c ICON PLC   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Itraconazole; Mycology; Onychomycosis; Prognostic factors; Terbinafine

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHYTE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ONYCHOMYCOSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; ANALYSIS OF VARIANCE; DOUBLE BLIND PROCEDURE; FOLLOW UP; MIDDLE AGED; SKIN DISEASE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; LOGISTIC MODELS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0036887246     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.05035.x     Document Type: Article

References (11)

1. Niewerth M, Korting HC. Management of onychomycosis. Drugs 1999; 58: 283-96.
2. Faergemann J, Zehender H, Boukhabza A et al. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol 1997; 77: 74-6.
3. Evans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. Br Med J 1999; 318: 1031-5.
4. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-4.
5. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001; 44: 479-84.
6. Sigurgeirsson B, Olafsson JH, Steinsson JT et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-7.
7. Gupta AK, Konnikov N, Lynde CW et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to antifungal agents. Eur J Dermatol 1999; 9: 633-8.
8. Baran R, De Donker P. Lateral edge involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1995; 76: 82-3.
9. Heikkila H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol 1997; 77: 70-1.
10. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189-90.
11. Hiruma M, Matsushita A, Kobayashi M, Ogawa H. One week pulse therapy with itraconazole (200 mg/day) for onychomycosis. Evaluation of treatment according to background information. Mycoses 2001; 44: 87-93.